KAG-308 is a novel, potent, selective and orally bioactive agonist of the prostaglandin E2 receptor EP4, it selectively activated EP4 and potently inhibited tumor necrosis factor-α production in peripheral whole blood and T cells, shows a Ki and an EC50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor. . It shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by orally bioavailable administration.

纯度：≥98%

CAS：1215192-68-9